Thyroid cancer in a long-term nonprogressor HIV-1 infection

Phatak, Uday A; Chitale, PV; Jagdale, Rakhi V

doi:10.4103/0253-7184.167175

Cited by 2 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, there are no data on managing immunosuppressed patients with advanced TC who are amenable to systemic treatment. Current published reports of TC patients mainly focus on the treatment of local disease with curative intent and the characteristics of immunosuppression 50‐52 . Any conclusions are based on different immunosuppression scenarios.…”

Section: Discussionmentioning

confidence: 99%

“…Current published reports of TC patients mainly focus on the treatment of local disease with curative intent and the characteristics of immunosuppression. 50 , 51 , 52 Any conclusions are based on different immunosuppression scenarios. So far, the management of immunocompromised patients with advanced malignancies remains a challenge for clinicians.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer

Basté

2022

Cancer Medicine

View full text Add to dashboard Cite

In this article, we focus on a variety of immunosuppression scenarios and whether multikinase inhibitors, as systemic therapy for advanced thyroid carcinoma (TC), could be useful for the treatment of immunocompromised patients with TC.Lenvatinib and sorafenib, among other MKIs, have become the standard of care for advanced TC based on their efficacy data and despite their adverse effects.Currently, published data on MKIs in immunosuppressed patients are scarce.Secondary malignancies can arise in immunosuppressed patients who have undergone solid organ transplantation, human immunodeficiency virus-infected patients, and hematopoietic stem cell transplant recipients. This review will explore different immunosuppression settings, the risk of secondary malignancies in immunosuppressed patients, and the special characteristics of this population. Some considerations regarding anticancer treatment in immunosuppressed patients with advanced malignancies are reviewed. K E Y W O R D Simmunosuppressed patients, multikinase inhibitors, systemic treatment, thyroid carcinoma How to cite this article: Basté Rotllan N. Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer

Basté

2022

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Lung cancer was the most frequent NADCs in our subject, followed by thyroid cancer. Data about prevalence of thyroid cancer were controversial 28 , 29 . Screening of thyroid cancer is easy to implement by ultrasound in order to provide a rapid treatment.…”

Section: Discussionmentioning

confidence: 99%

A retrospective study of distribution of HIV associated malignancies among inpatients from 2007 to 2020 in China

Wang

Pan

Zhao

et al. 2021

Sci Rep

View full text Add to dashboard Cite

HIV-associated malignancies are responsible for morbidity and mortality increasingly in the era of potent antiretroviral therapy. This study aimed to investigate the distribution of HIV-associated malignancies among inpatients, the immunodeficiency and the effect of antiretroviral therapy (ART) on spectrum of HIV-associated malignancies. A total of 438 cases were enrolled from 2007 to 2020 in Beijing Ditan Hospital. Demographic, clinical and laboratory data, managements, and outcomes were collected and analyzed retrospectively. Of 438 cases, 433 were assigned to non-AIDS-defining cancers (NADCs) (n = 200, 45.7%) and AIDS-defining cancers (ADCs) (n = 233, 53.2%), 5 (1.1%) with lymphoma were not specified further. No significant change was observed in the proportion of NADCs and ADCs as time goes on. Of NADCs, lung cancer (n = 38, 19%) was the most common type, followed by thyroid cancer (n = 17, 8.5%). Patients with ADCs had lower CD4 counts(104.5/μL vs. 314/μL), less suppression of HIVRNA(OR 0.23, 95%CI 0.16–0.35) compared to those with NADCs. ART did not affect spectrum of NADCs, but affect that of ADCs (between patients with detectable and undetectable HIVRNA). ADCs remain frequent in China, and NADCs play an important role in morbidity and mortality of HIV positive population.

show abstract

Thyroid cancer in a long-term nonprogressor HIV-1 infection

Cited by 2 publications

References 7 publications

Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer

Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer

A retrospective study of distribution of HIV associated malignancies among inpatients from 2007 to 2020 in China

Contact Info

Product

Resources

About